Thermo Fisher Scientific (TMO)
(Delayed Data from NYSE)
$618.46 USD
-5.75 (-0.92%)
Updated Sep 11, 2024 04:00 PM ET
After-Market: $618.47 +0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$618.46 USD
-5.75 (-0.92%)
Updated Sep 11, 2024 04:00 PM ET
After-Market: $618.47 +0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
Zacks News
Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
CVS Health (CVS) Beats on Q3 Earnings, Raises '19 EPS Guidance
by Zacks Equity Research
CVS Health's (CVS) strong year-over-year growth in the top line is aided by a robust performance at the Pharmacy Services segment.
Phibro's (PAHC) Q1 Earnings & Revenues Fall Y/Y, Margins Down
by Zacks Equity Research
Phibro (PAHC) exhibits a dismal first-quarter performance on a decline in revenues at core business segments.
HMS Holdings (HMSY) Q3 Earnings Top Estimates, Revenues Miss
by Zacks Equity Research
HMS Holdings' (HMSY) Q3 earnings benefit from higher revenues at Analytical Services unit and strong 2019 outlook.
Avanos (AVNS) Earnings and Revenues Miss Estimates in Q3
by Zacks Equity Research
Avanos (AVNS) third-quarter results benefit from higher revenues and strong segmental performance.
Zacks.com featured highlights include: SYNNEX, Thermo Fisher Scientific, Allstate, Intel and Target
by Zacks Equity Research
Zacks.com featured highlights include: SYNNEX, Thermo Fisher Scientific, Allstate, Intel and Target
Inogen's (INGN) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Softness in domestic and international business-to-business revenues impact Inogen's (INGN) Q3 results.
DaVita (DVA) Earnings and Revenues Beat Estimates in Q3
by Zacks Equity Research
DaVita (DVA) raises guidance for 2019 following impressive Q3 results.
STERIS' (STE) Q2 Earnings Surpass Estimates, FY20 View Up
by Zacks Equity Research
STERIS (STE) witnesses solid revenue growth across each of its operating segments in the second quarter of fiscal 2020.
Zimmer Biomet (ZBH) Q3 Earnings Top, Operating Margin Falls
by Zacks Equity Research
Zimmer Biomet (ZBH) gains from strong sales growth across all geographies and most operating segments in Q3.
Hill-Rom's (HRC) Q4 Earnings Beat on Strong Global Sales
by Zacks Equity Research
Internationally, Asia Pacific, Latin America and EMEA registers strong revenue growth for Hill-Rom (HRC).
Allscripts (MDRX) Q3 Earnings Beat Estimates, Improve Y/Y
by Zacks Equity Research
Allscripts (MDRX) third-quarter results gain from growth in bookings and solid segmental performance. Contraction in both gross and operating margins remains a woe.
Luminex (LMNX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Luminex's (LMNX) Q3 earnings benefit from higher revenues and solid performance across System Sales, Consumable Sales and Service Revenues. However, gross margin contraction remains a woe.
Myriad Genetics (MYGN) Lags Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Myriad Genetics (MYGN) observes a decline in Hereditary Cancer, GeneSight, Vectra as well as Other testing revenues in Q1.
Henry Schein (HSIC) Q3 Earnings Top Estimates, Revenues Lag
by Zacks Equity Research
Henry Schein (HSIC) registers solid performance across its key operating businesses in Q3.
Becton, Dickinson (BDX) Beats on Q4 Earnings and Revenues
by Zacks Equity Research
Becton, Dickinson (BDX) gains from solid segmental contributions in Q4.
Tandem Diabetes (TNDM) Q3 Loss Narrows Y/Y, Sales Improve
by Zacks Equity Research
Tandem Diabetes (TNDM) exhibits a robust performance in the third quarter of 2019, fueled by strong domestic demand.
5 Excellent Dividend Growth Stocks on Sale
by Sweta Killa
Stocks with a strong history of dividend growth year over year form a healthy portfolio with a greater scope of capital appreciation.
Intersect ENT (XENT) Reports Q3 Loss, Revenues Meet Estimates
by Zacks Equity Research
Intersect ENT (XENT) exhibits a dismal performance in the third quarter of 2019.
Haemonetics (HAE) Beats on Q2 Earnings, Raises '20 EPS View
by Zacks Equity Research
Haemonetics (HAE) delivers robust fiscal second-quarter revenues, fueled by strong performances in Plasma and Hospital segments.
Surmodics (SRDX) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Surmodics (SRDX) continues to gain from core Medical Devices unit, which saw significant contribution from the SurVeil deal with Abbott in Q4.
Bio-Rad (Bio) Q3 Earnings Beat Estimates on All-Line Growth
by Zacks Equity Research
Growing strength in many of Bio-Rad's (Bio) key product lines across major geographic regions buoys investors' optimism on the stock.
Syneos Health (SYNH) Tops Q3 Earnings Estimates, Ups EPS View
by Zacks Equity Research
Syneos Health (SYNH) exhibits robust topline performance in the third quarter, backed by strong segmental growth.
Integer Holdings (ITGR) Beats on Q3 Earnings, Revenues Miss
by Zacks Equity Research
Integer Holdings' (ITGR) Q3 earnings benefit from higher revenues and strong 2019 outlook.
Bruker (BRKR) Beats Q3 Earnings Estimates, Ups EPS Guidance
by Zacks Equity Research
Bruker (BRKR) delivers robust third-quarter revenue growth, backed by strong segmental performances.
PRA Health (PRAH) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
PRA Health (PRAH) raises 2019 EPS view after a solid third-quarter show.